Government’s public enthusiasm looks premature given the lack of available data
The UK government recently announced an “innovative and ground-breaking collaboration” with the drug company Novartis to launch a clinical trial of inclisiran, a new cholesterol lowering drug.1 In addition, health officials said that they would provide the “cutting edge new cholesterol treatment” to patients once it was approved by regulators and the National Institute for Health and Care Excellence.2 They also stated that early results suggest that if 300 000 patients are treated each year, 55 000 heart attacks and strokes could be prevented and 30 000 lives saved over 10 years.1
This collaboration comes in the context of increasing uncertainty about the use of statins,3 and the newer PCSK9 inhibitors, which are expensive,2 and may not have lived up to expectations in terms of reductions in cardiovascular deaths or all-cause mortality.4 Inclisiran is not yet approved by any regulatory body worldwide, and there is currently no reliable publicly available evidence on its effect on cardiovascular disease or long term safety and cost effectiveness.
Inclisiran is …

中文翻译：

---

英国与inclisiran达成交易。

鉴于缺乏可用数据
，政府的公众热情似乎为时过早。英国政府最近宣布与制药公司诺华（Novartis）进行“创新且开创性的合作”，以开展新型降胆固醇药物inclisiran的临床试验。1此外，卫生官员表示，一旦获得监管机构和美国国立卫生与医疗保健研究院的批准，他们将为患者提供“最先进的新胆固醇治疗”。2他们还指出，早期结果表明，如果每年治疗30万患者，则可以预防55,000例心脏病和中风，并在10年内挽救3万条生命。1个
这种合作是在他汀类药物，3和较新的PCSK9抑制剂的使用越来越不确定的情况下进行的，后者价格昂贵，2并且在减少心血管疾病死亡或全因死亡率方面可能没有达到预期。4 Inclisiran尚未获得全球任何监管机构的批准，并且目前尚无可靠的公开证据可证明其对心血管疾病的影响或长期安全性和成本效益。
Inclisiran是……